MRI and Recurrence Rates in Women With DCIS
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.
This large retrospective study was done to evaluate the association of MRI and long-term outcomes, meaning locoregional recurrence and contralateral breast cancer in women with DCIS. Researchers found that there was no difference between the rates of locoregional recurrence and those women with or without a perioperative MRI at 5 and 8 years. There was also no significant difference observed in the rates of locoregional recurrence at 5 or 8 years in women who did not have radiation therapy, though theoretically these patients would benefit most from the addition of MRI. There was also no difference in the rates of contralateral breast cancer between women with and without MRI.
Clinical Pearls
Ultimately, Pilewskie says, these data add to the literature that MRI use for women with DCIS is not associated with improved outcomes.
- This study was done to evaluate the association of perioperative MRI and long-term outcomes
- There was no association observed between perioperative MRI and locoregional recurrence rates for patients with DCIS, even when radiotherapy was not given
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
